PPARγ-mediated insulin sensitization: The importance of fat versus muscle

American Journal of Physiology - Endocrinology and Metabolism

Volumn 288, Issue 2 51-2, 2005, Pages

  Kintscher, Ulrich ^a   Law, Ronald E ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TAKEDA PHARMACEUTICALS   (United States)

Author keywords

Diabetes; Glitazone; Peroxisome proliferator activated receptor

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; ANTIDIABETIC AGENT; GLITAZONE DERIVATIVE; GLUCOSE; INSULIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; DRUG RECEPTOR BINDING; DRUG TARGETING; GLUCOSE HOMEOSTASIS; HOMEOSTASIS; HUMAN; HYPERLIPIDEMIA; INSULIN SENSITIVITY; KNOCKOUT MOUSE; LIVER; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; SKELETAL MUSCLE; ANIMAL; INSULIN RESISTANCE; METABOLISM; MOUSE; MOUSE MUTANT; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADIPOSE TISSUE; ANIMALS; INSULIN; INSULIN RESISTANCE; MICE; MICE, KNOCKOUT; MUSCLE, SKELETAL; PPAR GAMMA; SIGNAL TRANSDUCTION;

EID: 13744249406     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00440.2004     Document Type: Review

References (38)

1. Braissant O, Foufelle F, Scotto C, Dauca M, and Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137: 354-366, 1996.
2. Desvergne B and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20: 649-688, 1999.
3. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, and Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83: 803-812, 1995.
4. Frias JP, Yu JG, Kruszynska YT, and Olefsky JM. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care 23: 64-69, 2000.
5. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, Vinson C, Eckhaus M, and Reitman ML. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 105: 271-278, 2000.
6. Glass CK and Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14: 121-141, 2000.
7. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 13: 51-59, 2002.
8. He W, Barak Y, Hevener A, Olson P, Liao D, Le J, Nelson M, Ong E, Olefsky JM, and Evans RM. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA 100: 15712-15717, 2003.
9. Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Wilkes J, Evans RM, and Olefsky J. Muscle-specific Pparg deletion causes insulin resistance. Nat Med 9: 1491-1497, 2003.
10. Hsueh WA and Law R. The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease. Am J Cardiol 92: 3J-9J, 2003.
11. Jackson SM, Parhami F, Xi XP, Berliner JA, Hsueh WA, Law RE, and Demer LL. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 19: 2094-2104, 1999.
12. Kintscher U, Wakino S, Bruemmer D, Goetze S, Graf K, Hsueh W, and Law R. TGF-beta(1) induces peroxisome proliferator-activated receptor gamma1 and gamma2 expression in human THP-1 monocytes. Biochem Biophys Res Commun 297: 794, 2002.
13. Koutnikova H and Auwerx J. Regulation of adipocyte differentiation. Ann Med 33: 556-561, 2001.
14. Koutnikova H, Cock TA, Watanabe M, Houten SM, Champy MF, Dierich A, and Auwerx J. Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice. Proc Natl Acad Sci USA 100: 14457-14462, 2003.
15. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, and Kadowaki T. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4: 597-609, 1999.
16. Lee CH, Olson P, and Evans RM. Minireview. Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144: 2201-2207, 2003.
17. Lewis GF, Carpentier A, Adeli K, and Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23: 201-229, 2002.
18. Loviscach M, Rehman N, Carter L, Mudaliar S, Mohadeen P, Ciaraldi TP, Veerkamp JH, and Henry RR. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. Diabetologia 43: 304-311, 2000.
19. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, and Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. War Med 8: 731-737. 2002.
20. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, and Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50: 2094-2099, 2001.
21. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, and DeFronzo RA. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24: 710-719, 2001.
22. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, Feigenbaum L, Lee E, Aoyama T, Eckhaus M, Reitman ML, and Vinson C. Life without white fat: a transgenic mouse. Genes Dev 12: 3168-3181, 1998.
23. Muoio DM, Way JM, Tanner CJ, Winegar DA, Kliewer SA, Houmard JA, Kraus WE, and Dohm GL. Peroxisome proliferator-activated receptor-alpha regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes 51: 901-909, 2002.
24. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, and Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331: 1188-1193, 1994.
25. Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, Spiegelman BM, and Kahn CR. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 112: 608-618, 2003.
26. Perseghin G, Ghosh S, Gerow K, and Shulman GI. Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes 46: 1001-1009, 1997.
27. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C, Vanzulli A, Testolin G, Pozza G, Del Maschio A, and Luzi L. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 48: 1600-1606, 1999.
28. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, and Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 43: 278-284, 2000.
29. Ren D, Collingwood TN, Rebar EJ, Wolffe AP, and Camp HS. PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev 16: 27-32, 2002.
30. Ribon V, Johnson JH, Camp HS, and Saltiel AR. Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene. Proc Natl Acad Set USA 95: 14751-14756, 1998.
31. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, and Glass CK. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95: 7614-7619, 1998.
32. Saladin R, Fajas L, Dana S, Halvorsen YD, Auwerx J, and Briggs M. Differential regulation of peroxisome proliferator activated receptor gammal (PPARgamma1) and PPARgamma2 messenger RNA expression in the early stages of adipogenesis. Cell Growth Differ 10: 43-48, 1999.
33. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 106: 171-176, 2000.
34. Smith U, Gogg S, Johansson A, Olausson T, Rotter V, and Svalstedt B. Thiazolidinediones (PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB J 15: 215-220, 2001.
35. Tontonoz P, Hu E, and Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79: 1147-1156, 1994.
36. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, and Flier JS. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 99: 2416-2422, 1997.
37. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Kara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, and Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423: 762-769, 2003.
38. Zhang J, Fu M, Cui T, Xiong C, Xu K, Zhong W, Xiao Y, Floyd D, Liang J, Li E, Song Q, and Chen YE. Selective disruption of PPAR-gamma 2 impairs the development of adipose tissue and insulin sensitivity. Proc Natl Acad Sci USA 101: 10703-10708, 2004.